Ricursive Intelligence | $300,000,000 | (Jan 28, 2026)
Nerd Apply | $3,200,000 | (Jan 28, 2026)
Fiddler AI | $30,000,000 | (Jan 28, 2026)
Certified by Founder
Lodge
DiogenX
start up
France
- Marseille
- 11/05/2023
- Series A
- $30,056,125
DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for millions of Diabetic patients around the world.
Our lead program, originating from Dr Patrick Collombat’s laboratory, is based on a new approach targeting beta-cell failure throughout the stimulation of beta-cell functional recovery in diabetes. This novel mode of action will provide a unique solution to rebalance glucose/insulin homeostasis and thus offer clear clinically meaningful benefits.
DiogenX is headquartered in Marseille, with labs in Nice (France).
- Industry Biotechnology
- Website https://diogenx.com/
- LinkedIn https://www.linkedin.com/company/diogenx/
Jelou AI | $10,000,000 | (Jan 28, 2026)
Concourse | $12,000,000 | (Jan 28, 2026)
Risotto | $10,000,000 | (Jan 28, 2026)
Summize | $50,000,000 | (Jan 28, 2026)
FLORA(US) | $42,000,000 | (Jan 28, 2026)
Fortitude Biomedicines | $13,000,000 | (Jan 28, 2026)
Chamelio | $10,000,000 | (Jan 28, 2026)
Opendate | $14,000,000 | (Jan 28, 2026)
Memcyco | $37,000,000 | (Jan 28, 2026)